Skip to content
HeyJared

Jim Van Meerten

Reporter

Indexed articles, last 90 days
42
Latest publication
Sep 22, 2026
Outlet visibility, for yahoo.com
Top 1K sites
Earliest in this view
Jul 6, 2026

Latest articles

  1. Article · Sep 22, 2026 · Jim Van Meerten

    This Stock Is Trading at New All-Time Highs and Looks Like a Great Long-Term Winner (opens the original)

    Excerpt · English

    Read excerpt

    Karat Packaging (KRT) demonstrates strong technical momentum and is trading at a new all-time high. Shares are up more than 110% over the past year. KRT has projected revenue growth of 12.01% this year and 8.47% next year. Analyst sentiment is mixed. The consensus leans "Strong Buy," but some see the stock as overvalued. Valued at $1 billion, Karat Packaging (KRT) is a specialty distributor and manufacturer of disposable foodservice products and related items. Its products include food and take-

  2. Article · Sep 21, 2026 · Jim Van Meerten

    Practice Caution with This Hot Stock Up 493% in the Past Year (opens the original)

    Excerpt · English

    Read excerpt

    Twist Bioscience (TWST) has surged 493% over 52 weeks, maintaining strong technical momentum. Shares just hit a new all-time high and has a 100% "Buy" technical opinion. However, its RSI of 72.95 and high short interest signal potential overextension. Consensus price targets are well below current levels, suggesting limited upside. Valued at $10.47 billion, Twist Bioscience (TWST) is a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample prep

  3. Article · Sep 17, 2026 · Jim Van Meerten

    Natera Stock Has Excellent Technical ‘DNA’ as NTRA Sets a New All-Time High (opens the original)

    Excerpt · English

    Read excerpt

    Natera (NTRA) demonstrates strong technical momentum, with shares hitting a new all-time high. Shares are up more than 105% over the past year. Valuation concerns persist, as Morningstar sees NTRA as 33% overvalued and multiple analysts rate it a "Hold" despite bullish technicals. I recommend holding NTRA while it trades above its 50-day moving average. Valued at $50 billion, Natera (NTRA) offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. I found to

  4. Article · Sep 16, 2026 · Jim Van Meerten

    Avantor Stock Has Strong Technical Momentum, But Make Sure Your Stop Losses Are Tight (opens the original)

    Excerpt · English

    Read excerpt

    Avantor (AVTR) exhibits strong technical momentum, recently setting a new year-to-date high. Shares are up more than 22% over the past year. AVTR maintains a 100% "Buy" technical opinion from Barchart. Most analysts see AVTR as undervalued, but I recommend a tight stop loss given its volatility and only moderate fundamental outlook. Valued at $10.44 billion, Avantor (AVTR) is a provider of critical products and services primarily to the biopharma, healthcare, education, government, advanced tech

  5. Article · Sep 15, 2026 · Jim Van Meerten

    Marathon Petroleum Stock Just Hit New Highs, But Oil Price Risks Remain (opens the original)

    Excerpt · English

    Read excerpt

    Marathon Petroleum (MPC) exhibits strong technical momentum, recently hitting a new all-time high. Shares are up more than 120% over the past year. MPC maintains a 100% "Buy" technical opinion from Barchart. Future performance is highly sensitive to refining margins and oil prices, with downside risk if oil drops to $75 per barrel. Valued at $116 billion, Marathon Petroleum (MPC) is a leading independent refiner, transporter, and marketer of petroleum products. The company came into existence fo

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Audience

Top 1K sites

For yahoo.com, the outlet · Measured Aug 1, 2026

Website popularity band, not a count of readers or article views.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about Jim Van Meerten